Table II.

Joint effects survival analysis of CCR gene expression levels with overall survival in patients with early-stage pancreatic ductal adenocarcinoma derived from The Cancer Genome Atlas database.

Group	CCR5	CCR6	CCR9	Patients (n)	Number of events	Median survival time (days)	Crude HR (95% CI)	Crude P-value	Adjusted HR (95% CI)	Adjusted P-valuea
A	Low	Low		45	32	381	1		1
B	Low	High		11	7	476	0.703 (0.307–1.612)	0.406	0.996 (0.374–2.651)	0.994
C	High	Low		11	7	603	0.451 (0.196–1.038)	0.061	0.803 (0.283–2.280)	0.680
D	High	High		45	32	591	0.386 (0.218–0.681)	0.010	0.434 (0.226–0.833)	0.012
I	Low		Low	35	24	393	1		1
II	Low		High	21	15	381	1.469 (0.759–2.841)	0.253	0.780 (0.367–1.657)	0.518
III	High		Low	21	13	517	0.846 (0.430–1.667)	0.630	1.158 (0.550–2.437)	0.699
IV	High		High	35	17	702	0.345 (0.178–0.667)	0.002	0.236 (0.107–0.520)	<0.001
A		Low	Low	37	26	458	1		1
B		Low	High	19	13	470	1.020 (0.521–1.998)	0.954	0.568 (0.256–1.261)	0.165
C		High	Low	19	11	695	0.828 (0.412–1.702)	0.624	0.931 (0.446–1.943)	0.849
D		High	High	37	19	518	0.438 (0.235–0.817)	0.009	0.284 (0.136–0.595)	0.001
1	Low	Low	Low	30	21	458	1		1
2	Low	Low	High	27	19	375	1.094 (0.585–2.047)	0.778	0.874 (0.451–1.692)	0.689
	High	Low	Low	–	–	–
	Low	High	Low	–	–	–
3	Low	High	High	24	14	518	0.667(0.338–1.316)	0.243	0.747(0.347–1.609)	0.457
	High	High	Low	–	–	–
	High	Low	High	–	–	–
4	High	High	High	31	15	913	0.350(0.172–0.711)	0.004	0.253(0.112–0.574)	0.001

^aAdjusted for histological grade, radiation therapy, radical resection and targeted molecular therapy using the multivariate Cox proportional hazards regression model. CCR, C-C motif chemokine receptor; HR, hazard ratio; CI, confidence interval.